Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,259 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: I-START Clear all
Active, not recruiting Phase 3 Interventional

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

NCT04379570
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
Interventions
Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Questionnaire Administration, Quality-of-Life Assessment
Other · Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
526
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

NCT02008383
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Panitumumab, Cabozantinib
Biological · Drug
Lead sponsor
John Strickler, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 27, 2026, 7:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

NCT05074290
View directory record Official record
Conditions
Breast Cancer
Interventions
Epidiferphane, Taxane Chemotherapy
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)

NCT01252797
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery (15 Gy), Stereotactic Radiosurgery (12 Gy)
Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 27, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

NCT00053950
View directory record Official record
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions
pyrazoloacridine, filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, pharmacological study
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Sleep To Reduce Incident Depression Effectively

NCT03322774
View directory record Official record
Conditions
Insomnia, Primary, Major Depressive Disorder, Rumination
Interventions
digital Cognitive Behavioral Therapy for Insomnia, face-to-face Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education Control
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section

NCT02960113
View directory record Official record
Conditions
Nausea, Vomiting, Satisfaction
Interventions
scopolamine patch, acupressure point P6
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 27, 2026, 7:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

NCT00895960
View directory record Official record
Conditions
Glioblastoma, CNS Disease, Brain Diseases
Interventions
Dasatinib, RT (Radiotherapy), TMZ (Temozolomide)
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

NCT01124760
View directory record Official record
Conditions
Pharmacokinetics
Interventions
AZD9742, Diltiazem, ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer

NCT00593060
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma
Interventions
Temsirolimus, Cetuximab
Drug
Lead sponsor
Jeffrey W. Clark, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 27, 2026, 7:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

NCT04711824
View directory record Official record
Conditions
Breast Cancer, Brain Metastases, Adult
Interventions
Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy
Drug · Radiation
Lead sponsor
Colette Shen
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 27, 2026, 7:10 AM EDT
Suspended Phase 2 Interventional

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT06538389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT00940524
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Mitoxantrone, Cytarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

NCT00045305
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

NCT02311582
View directory record Official record
Conditions
Malignant Glioma
Interventions
MK-3475, MRI-guided laser ablation
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 27, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

NCT00573404
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
imatinib mesylate, sunitinib malate, pharmacological study
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 27, 2026, 7:10 AM EDT
Withdrawn Not applicable Interventional

A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder

NCT01658748
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS, Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
25 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

ENGAGED: E-Networks Guiding Adherence to Goals for Exercise and Diet

NCT01051713
View directory record Official record
Conditions
Obesity
Interventions
Technology Supported, Standard
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 27, 2026, 7:10 AM EDT
Not yet recruiting Not applicable Interventional

Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial

NCT07606313
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Cancer, Functional Limitation
Interventions
Functional Resistance Training, Stretching, Delayed Functional Resistance Training
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 27, 2026, 7:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

NCT03480152
View directory record Official record
Conditions
Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer
Interventions
National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

NCT02018926
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Mocetinostat, Azacitidine
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Miami Lakes, Florida • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 27, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

NCT01874184
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 27, 2026, 7:10 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 27, 2026, 7:10 AM EDT